Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Determine the recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab
in subjects with advanced cancer.

Inclusion criteria for Phase Ib and II:

1. Patient at least 18 years old and has definitive histologically or cytologically
confirmed metastatic solid tumor.

2. Patient has one or more metastatic tumors measurable by CT scan (or PET/CT, if patient
is allergic to CT contrast media). Tumor sites that are considered measureable must
not have received prior radiation therapy. For metastatic tumors not measurable by CT
and/or PET/CT, there needs to be tumor measuring at least 1cm in one dimension by
digital calipers on physical exam.

3. Patients can be enrolled only on one of the treatment arms on this trial.

4. The investigator will select the appropriate treatment arm for the patient with the
following requirements: (a) Patients cannot have had prior progression or intolerance
on the single agent chemotherapy and then enrolled on an arm with that same single
agent chemotherapy plus nivolumab (b) The chemotherapy on the arm selected must be
considered standard of care or its components listed in the NCCN guidelines
(www.nccn.org) for that cancer type.

5. Have recovered from acute toxicities of prior treatment:

- > 3 weeks must have elapsed since receiving any investigational agent.

- > 2 weeks must have elapsed since receiving any radiotherapy, or ≥ 3 weeks or 5
half-lives whichever is shorter for treatment with cytotoxic or biologic agents (
≥ 6 weeks for mitomycin or nitrosoureas). Chronic treatment with
non-investigational gonadotropin-releasing hormone analogs or other hormonal or
supportive care is permitted.

6. Patient has adequate biological parameters as demonstrated by the following blood
counts at time of screening:

7. Absolute neutrophil count (ANC) > 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 9
g/dL. Subject can be given packed red blood cell transfusion

8. Calculated creatinine clearance > 40 ml/min by Cockroft-Gault equation:

[CreatClear = Sex * ((140 - Age) / (SerumCreat)) * (Weight / 72); where Sex = 1 for
men and 0.85 for women], total bilirubin 1.5 times the upper limit of normal (ULN)
range, AST/ALT ≤ 3 times the upper limit of normal (ULN) range.

9. Thyroid stimulating hormone (TSH) within institutional normal limits. If TSH is above
the upper limit of normal range, then a free T4 within institutional normal limits is
acceptable. If thyroid replacement therapy is initiated then patient may be screened
and enrolled once the above criterion is met.

10. Persistent prior systemic therapy non-hematologic AE grade ≤ 2 (except alopecia or
correctable electrolyte abnormality with supplementation)

11. Patient has a Karnofsky performance status (KPS) ≥ 70.

12. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
sterile) must be willing to use an acceptable contraceptive method (abstinence, oral
contraceptive or double barrier method) for the duration of the study and for 5 months
following the last dose of nivolumab and 30 days following the last dose of
chemotherapy on this trial on this trial, and must have a negative urine or serum
pregnancy test within 2 weeks prior to beginning treatment on this trial. If a female
subject or female partner of a male subject becomes pregnant during this period then
patient will be recommended to seek appropriate obstetric care. The study will not be
monitoring subjects or female partners of subjects for pregnancy after the last dose
of study drug or chemotherapy.

Exclusion Criteria for Phase Ib and II:

1. Active clinically serious infection > CTCAE (version 4.03) Grade 2.

2. Serious non-healing wound, ulcer, or bone fracture.

3. Patient has known brain metastases. Baseline imaging of the brain is required within
28 days prior to randomization.

4. Prior therapy with a mammalian target of rapamycin (mTOR) inhibitor for the RCC
subjects, prior therapy with irinotecan or topotecan for NSCLC subjects, and prior
therapy with irinotecan for CRC patients.

5. Inability to complete informed consent process and adhere to the protocol treatment
plan and follow-up requirements.

6. Patient has known active infection with HIV, hepatitis B, or hepatitis C (patients are
NOT required to be tested for the presence of such viruses prior to therapy on this
protocol).

7. Requiring daily corticosteroid dose ≥ 10 mg prednisone or equivalent per day.

8. Patient has undergone major surgery, other than diagnostic surgery (e.g., surgery done
to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to
Day 1 of treatment in this study.

9. Patient has serious medical risk factors involving any of the major organ systems, or
serious psychiatric disorders, which could compromise the patient's safety or the
study data integrity.

10. Patient will be receiving any other anti-cancer therapy during participation in this
trial.

11. Prior treatment with nivolumab is not allowed. Prior receipt of other PD-1 inhibitors
or PD-L1 inhibitors is allowed.

12. Active or prior documented autoimmune disease requiring systemic treatment within the
past 2 years.